These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 36165733)

  • 21. A qualitative study of repeat naloxone administrations during opioid overdose intervention by people who use opioids in New York City.
    Parkin S; Neale J; Brown C; Jones JD; Brandt L; Castillo F; Campbell ANC; Strang J; Comer SD
    Int J Drug Policy; 2021 Jan; 87():102968. PubMed ID: 33096365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overdose Education and Naloxone for Patients Prescribed Opioids in Primary Care: A Qualitative Study of Primary Care Staff.
    Binswanger IA; Koester S; Mueller SR; Gardner EM; Goddard K; Glanz JM
    J Gen Intern Med; 2015 Dec; 30(12):1837-44. PubMed ID: 26055224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increasing Naloxone Access and Prescribing for Patients on High-Dose Opioids From a Managed Care Pharmacy Health Plan Perspective.
    Hansgen JP; Robertson ML; Verzino EM; Manning LM
    J Pharm Pract; 2024 Dec; 37(6):1291-1296. PubMed ID: 38685768
    [No Abstract]   [Full Text] [Related]  

  • 24. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
    Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
    J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acceptability of Naloxone Co-Prescription Among Primary Care Providers Treating Patients on Long-Term Opioid Therapy for Pain.
    Behar E; Rowe C; Santos GM; Coffa D; Turner C; Santos NC; Coffin PO
    J Gen Intern Med; 2017 Mar; 32(3):291-295. PubMed ID: 27815762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities.
    Lai Joyce Chun K; Olsen A; Taing MW; Clavarino A; Hollingworth S; Dwyer R; Middleton M; Nielsen S
    Res Social Adm Pharm; 2019 Aug; 15(8):1014-1020. PubMed ID: 30926251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
    Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
    Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal.
    Nielsen S; Menon N; Larney S; Farrell M; Degenhardt L
    Addiction; 2016 Dec; 111(12):2177-2186. PubMed ID: 27367125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches.
    Green TC; Donovan E; Klug B; Case P; Baird J; Burstein D; Tapper A; Walley AY; Bratberg J
    J Am Pharm Assoc (2003); 2020; 60(5):740-749. PubMed ID: 32334964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient acceptance of naloxone resulting from targeted intervention from community pharmacists to prevent opioid misuse and accidental overdose.
    Skoy E; Werremeyer A; Steig J; Eukel H; Frenzel O; Strand M
    Subst Abus; 2021; 42(4):672-677. PubMed ID: 33044896
    [No Abstract]   [Full Text] [Related]  

  • 31. Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain.
    Coffin PO; Behar E; Rowe C; Santos GM; Coffa D; Bald M; Vittinghoff E
    Ann Intern Med; 2016 Aug; 165(4):245-52. PubMed ID: 27366987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Like it was just everyday business": A qualitative study of pharmacy-based naloxone and syringe customer experience.
    Gray M; Shin SS; Silcox J; Flores D; Bolivar D; Irwin AN; Floyd AS; Bratberg J; Boggis JS; Hartung DM; Green TC
    J Am Pharm Assoc (2003); 2023; 63(3):838-846. PubMed ID: 36872182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacists' perceptions regarding feasibility, acceptability, and usefulness of student-delivered naloxone education services in community pharmacy: A mixed methods study in Alabama.
    Hohmann L; Maxson R; McDowell L
    J Am Pharm Assoc (2003); 2023; 63(6):1731-1742.e4. PubMed ID: 37619850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naloxone Prescribing and Education in Outpatient Pain Management and Palliative Care.
    Coons LM; Gardea Hart J; White A; Summers S
    J Pain Palliat Care Pharmacother; 2021 Jun; 35(2):100-105. PubMed ID: 33844624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Naloxone Knowledge and Attitudes Towards Overdose Response Among Family Members of People who Misuse Opioids.
    Resko SM; Pasman E; Hicks DL; Lee G; Ellis JD; O'Shay S; Brown S; Agius E
    J Community Health; 2024 Feb; 49(1):70-77. PubMed ID: 37450091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
    Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
    Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "That's why we're speaking up today": exploring barriers to overdose fatality prevention in Indianapolis' Black community with semi-structured interviews.
    Seo DC; Satterfield N; Alba-Lopez L; Lee SH; Crabtree C; Cochran N
    Harm Reduct J; 2023 Oct; 20(1):159. PubMed ID: 37891632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy.
    Hines KL; Garofoli GK; Garofoli MP; Elswick BM; Winstanley EL
    J Am Pharm Assoc (2003); 2020; 60(6):e205-e214. PubMed ID: 32800678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
    Melaragni F; Levy C; Pedrazzi J; Andersen M
    J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing pharmacists' knowledge, attitudes, and practices of opioid management within different patient populations.
    Martin SE; Hughes TD; Roller J; Ferreri SP
    J Am Pharm Assoc (2003); 2024; 64(2):414-421.e1. PubMed ID: 38049067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.